While the precise mechanism of mAb combinations is still being investigated, trastuzumab plus pertuzumab combined with chemotherapy is now part of the clinician’s armamentarium to treat HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.